ProVerum Limited Raises Significant Funds for Innovative BPH Treatment
ProVerum Limited Secures Major Financing for BPH Treatment
ProVerum Limited has recently announced the successful closing of an $80 million Series B equity financing to advance its innovative ProVee® System aimed at addressing benign prostatic hyperplasia (BPH). This funding round was led by MVM Partners, with contributions from new investors OrbiMed and the Ireland Strategic Investment Fund (ISIF), in addition to existing investors such as Gilde Healthcare Partners, Lightstone Ventures, Atlantic Bridge, and Enterprise Ireland.
Innovative Technology for BPH Treatment
The ProVee System offers a cutting-edge solution that utilizes a nitinol stent designed to gently reshape the enlarged prostate, thus relieving the uncomfortable lower urinary tract symptoms often associated with BPH. This system features a low profile, flexible, and steerable delivery mechanism with integrated imaging capabilities, matching the size of endoscopes commonly used in offices for BPH diagnosis. With this financing, ProVerum will accelerate preparations for the commercialization of the ProVee System.
Leadership Insights on Growth
Paul Bateman, the CEO of ProVerum, expressed enthusiasm about this funding, welcoming MVM, OrbiMed, and ISIF to the team. He stated, "This is an exciting time for the company as we prepare to commercialize our novel treatment for men with BPH.” Paul’s leadership, combined with the support from these investors, positions ProVerum for significant growth.
Strategic Additions to the Board
ProVerum has also recently expanded its Board of Directors by welcoming Hugo Harrod, a Partner at MVM Partners, and Dina Chaya, a Partner at OrbiMed. Their expertise will undoubtedly benefit ProVerum as it navigates the next stages of its growth and commercialization initiatives.
Investor Comments on the Company’s Future
Hugo Harrod remarked, "ProVerum exemplifies MVM's focus on disruptive medical products addressing areas of true unmet need. We look forward to applying our experience in commercial stage medical technology to support the Company through its next phase.” Meanwhile, OrbiMed's Dina Chaya reinforced their commitment, noting, "ProVerum has an innovative minimally invasive treatment for BPH and is led by a first-class team. We are delighted to support the Company in its growth journey.”
About ProVerum Limited
ProVerum Ltd. operates out of Dublin, focusing on creating novel minimally invasive technologies to tackle BPH. The ProVee® System remains an investigational device, limited by federal law to investigational use and not available for sale within the United States. For additional information, visit the official ProVerum website or connect via social media platforms.
About MVM Partners
MVM Partners has been a prominent investor in high-growth healthcare businesses since 1997, with operations in multiple global markets including Boston, London, and the San Francisco Bay Area. The firm’s extensive approach covers various segments like medical technology, pharmaceuticals, and digital health.
About OrbiMed
OrbiMed stands as a significant player in healthcare investment, managing over $17 billion in assets worldwide. The firm engages with businesses from startups to large corporations, providing tailored financing solutions that help build esteemed healthcare companies.
About the Ireland Strategic Investment Fund
The Ireland Strategic Investment Fund (ISIF) serves as a sovereign development fund aiming to stimulate economic activity and employment within the country. Managed by the National Treasury Management Agency, ISIF carefully invests in areas that bolster local growth.
Frequently Asked Questions
What does ProVerum's ProVee System do?
The ProVee System is designed to treat benign prostatic hyperplasia (BPH) by using a minimally invasive approach to alleviate lower urinary tract symptoms.
Who are the main investors in ProVerum's recent financing?
The financing was led by MVM Partners, with participation from OrbiMed, the Ireland Strategic Investment Fund, and several existing investors.
What is benign prostatic hyperplasia (BPH)?
BPH is a condition in which the prostate gland is enlarged, leading to various urinary symptoms in men, which can greatly affect their quality of life.
What are the future plans for ProVerum?
ProVerum plans to use the new funding to continue developing and preparing the ProVee System for commercialization in the near future.
Who is leading ProVerum Limited?
Paul Bateman serves as the CEO of ProVerum, guiding the company through its growth and product development phases.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.